证券代码：603983 证券简称：丸美生物 公告编号：2025-016 广东丸美生物技术股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.50元（含税） 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/9 | － | 2025/6/10 | 2025/6/10 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 22 日的2024年年度股东大会审议通过。 本次利润分配以方案实施前的公司总股本401,000,000股为基数，每股派发现 金红利0.50元（含税），共计派发现金红利200,500,000.00元（含税）。 三、 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | - ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [7]. Core Views - In 2024, the company achieved operating revenue of 2.97 billion, a year-on-year increase of 33.4%, and a net profit attributable to shareholders of 340 million, up 31.7%. The net profit excluding non-recurring items reached 330 million, growing by 73.9% [2][4]. - For Q1 2025, the company reported operating revenue of 850 million, a year-on-year growth of 28%, with a net profit attributable to shareholders of 140 million, increasing by 22.1% [2][4]. - The company's strategy of focusing on major products has been effective, with significant growth in key items such as the "Little Red Pen Eye Cream" and "Little Gold Needle" achieving GMV of 530 million and 350 million respectively, marking increases of 146% and 96% [9]. Summary by Sections Financial Performance - In 2024, the company’s revenue growth was driven by a strong performance in its main brand, which generated 2.06 billion in revenue, a 31.7% increase. The online and offline channels reported revenues of 2.54 billion and 430 million respectively, reflecting growth of 36% and 21% [9]. - The company’s net profit for Q1 2025 showed a year-on-year increase of 22%, with a net profit margin remaining stable despite rising sales expenses [9]. Product and Brand Strategy - The company continues to enhance its major product strategy, with the main brand and the "Lianhuo" brand expected to maintain robust growth. The eye care category saw a significant increase in average price, contributing to overall revenue growth [9]. Future Outlook - The company is projected to achieve net profits of 450 million, 580 million, and 750 million for the years 2025 to 2027, with corresponding EPS of 1.11, 1.44, and 1.87 [9].

Investment Rating - The investment rating for the company is "Buy" and is maintained [7] Core Insights - In 2024, the company achieved operating revenue of 2.97 billion yuan, a year-on-year increase of 33.4%; net profit attributable to the parent company was 340 million yuan, up 31.7%; and net profit excluding non-recurring items was 330 million yuan, growing by 73.9%. In Q1 2025, the company reported operating revenue of 850 million yuan, a year-on-year growth of 28%; net profit attributable to the parent company was 140 million yuan, increasing by 22.1%; and net profit excluding non-recurring items was 130 million yuan, up 28.6% [2][4] Summary by Sections Business Performance - The company continues to solidify its big product strategy, with the main brand maintaining high growth. In 2024, revenue growth rates for each quarter were 39%, 19%, 26%, and 48%, with a significant acceleration in Q4. The main brand, Marubi, generated revenue of 2.06 billion yuan, a year-on-year increase of 31.7%. The two core products, the Little Red Pen Eye Cream and the Little Gold Needle, achieved GMV of 530 million yuan and 350 million yuan, respectively, with year-on-year growth of 146% and 96%. The Love Fire brand generated revenue of 910 million yuan, up 40.7%, with six foundation products each exceeding 100 million yuan in annual GMV [13] Financial Forecast - For 2025-2027, the company is expected to achieve net profits attributable to the parent company of 450 million yuan, 580 million yuan, and 750 million yuan, respectively, corresponding to EPS of 1.11 yuan, 1.44 yuan, and 1.87 yuan per share [13][17]

证券代码：603983 证券简称：丸美生物 公告编号：2025-015 广东丸美生物技术股份有限公司 2024年年度股东大会决议公告 (一)股东大会召开的时间：2025 年 5 月 22 日 (二)股东大会召开的地点：广州天河区珠江新城冼村路 11 号保利威座大厦南塔 6 楼丸美生物会议室 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 122 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 336,471,849 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 83.9081 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由公司董事会召集，采用现场投票与网络投票相结合的方式召开。 因董事长孙怀庆出差在外不能现场主持本次股东大会，半数以上董事推选董事王 开慧先生主持本次股东大会。会议的召集和召 ...

广东信达律师事务所 股东大会法律意见书 中国 深圳 福田区 益田路 6001 号 太平金融大厦 11、12 楼 邮政编码：518038 11F/12F., TAIPING FINANCE TOWER, NO.6001 YITIAN ROAD, SHENZHEN, CHINA 电话（Tel.）：（0755）88265288 传真（Fax.）：（0755）88265537 网站（Website）：https://www.sundiallawfirm.com 广东信达律师事务所 关于广东丸美生物技术股份有限公司 2024 年年度股东大会的 法律意见书 信达会字（2025）第 177 号 致：广东丸美生物技术股份有限公司 广东信达律师事务所（以下简称"信达"）接受广东丸美生物技术股份有限 公司（下称"贵公司"）的委托，指派律师参加了贵公司 2024 年年度股东大会 （下称"本次股东大会"），并进行了必要的验证工作。现根据《中华人民共和 国公司法》（下称"《公司法》"）、《上市公司股东会规则》（下称"《股东 会规则》"）以及贵公司《公司章程》的规定，按照律师行业公认的业务标准、 道德规范和勤勉尽责精神，对本次股东大会的 ...

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT Guangdong Marubi Biotechnology Co., Ltd. Table of Content | Message from Chairman | 03 | | --- | --- | | About Marubi | 05 | | Recap of 2024 | 11 | | ESG Governance | 15 | | Theme Spotlight: Scientific | 19 | | Skincare, Rejuvenating with | | | Collagen "Core" Innovation | | Appendix 97 | Key Performance Table | 97 | | --- | --- | | Indicators Index | 101 | | About This Report | 105 | Steady Operation, Forging Sustainable "Beauty" Power 01 People-Oriented, Composi ...

广东丸美生物技术股份有限公司 2024 年年度股东大会会议资料 广东丸美生物技术股份有限公司 2024 年年度股东大会 会议资料 2025 年 5 月 22 日 1 广东丸美生物技术股份有限公司 2024 年年度股东大会会议资料 广东丸美生物技术股份有限公司 2024 年年度股东大会会议须知 各位股东及股东代表： 为维护投资者的合法权益，确保广东丸美生物技术股份有限公司（以下简称"公 司"）2024 年年度股东大会的顺利召开，依据中国证券监督管理委员会《上市公司 股东大会规则》等有关规定，制定会议须知如下： 一、公司根据《公司法》《证券法》《上市公司股东大会规则》和《公司章程》的 规定，认真做好召开股东大会的各项工作。 二、公司董事会办公室具体负责会议有关程序方面的事宜。 三、为保证股东大会的严肃性和正常秩序，切实维护与会股东（包含股东代表， 下同）的合法权益，除出席会议的股东、公司董事、监事、高级管理人员、公司聘 请的律师及董事会邀请的人员外，公司有权依法拒绝其他人员进入会场。 四、出席会议的股东须在会议召开前 15 分钟到达会议现场向董事会办公室办理 签到手续，并请按规定出示股票账户卡、持股凭证、身份证或 ...

证券代码：603983 证券简称：丸美生物 公告编号：2025-014 广东丸美生物技术股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东大会类型和届次 2024年年度股东大会 (二)股东大会召集人：董事会 至2025 年 5 月 22 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六)融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所上市公司自律监管指引第 1 号 — 规范运作》等有 关规定执行。 (七)涉及公开征集股东投票权 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (四)现场会议召开 ...

Investment Rating - The investment rating for the company is maintained as "Buy" [7] Core Views - The company has achieved high-quality revenue growth for nine consecutive quarters, with a revenue of 2.97 billion RMB in 2024, representing a year-on-year increase of 33.44%, and a net profit of 342 million RMB, up 31.69% year-on-year [1] - The main brand products, including the "Little Red Pen" eye cream and "Little Gold Needle" series, show strong momentum, with significant online sales growth [2] - The company is experiencing synergistic growth in both online and offline channels, with online revenue reaching 2.54 billion RMB in 2024, a year-on-year increase of 35.77% [3] Summary by Sections Revenue and Profitability - The company has reported a continuous double-digit revenue growth for nine quarters, with a net profit margin consistently above 9% [1] - In Q1 2025, the company achieved a revenue of 847 million RMB, a year-on-year increase of 28.01%, and a net profit of 135 million RMB, up 22.07% year-on-year [1] Product Performance - The "Little Red Pen" eye cream has been iterated to version 3.0, achieving an online GMV of 533 million RMB, a year-on-year increase of 146% [2] - The "Little Gold Needle" essence has also seen significant growth, with an online GMV of 350 million RMB, up 96% year-on-year [2] Cost and Expense Management - The sales expense ratio for 2024 was 55.0%, an increase of 1.19 percentage points year-on-year, reflecting increased investment in brand building and online competition [3] - The management expense ratio decreased to 3.7%, indicating improved cost efficiency [3] Profit Forecast and Valuation - The profit forecast for 2025-2027 has been adjusted, with expected net profits of 448 million RMB, 585 million RMB, and 758 million RMB respectively [4] - The target price has been raised to 50.40 RMB, based on a projected PE of 45 times for 2025 [4]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported strong performance in its major products, with online sales maintaining high growth [7] - The company has shown significant improvement in profitability and cost control, with gross margin increasing [7] - The dual-channel revenue growth is robust, with all four major product categories experiencing growth [7] - The company's brand strategy focusing on major products has enhanced user loyalty and brand performance [7] - The earnings forecast for 2025-2026 has been slightly adjusted downwards, but the long-term growth outlook remains positive [7] Financial Performance Summary - For 2024, total revenue is projected at 2,970 million, a year-on-year increase of 33.4% [7] - The net profit attributable to shareholders for 2024 is expected to be 341.63 million, up 31.7% year-on-year [7] - The gross margin for 2024 is forecasted to be 73.7%, an increase of 3.0 percentage points year-on-year [7] - Online revenue for 2024 is expected to reach 2,540 million, a growth of 35.8% [7] - The skincare category is projected to generate 1,125 million in revenue, a 21.6% increase [7] - The company's net profit margin for 2024 is estimated at 11.5%, a slight decrease of 0.2 percentage points year-on-year [7] Brand Performance Summary - The Marubi brand is expected to generate 2,055 million in revenue for 2024, a 31.69% increase [7] - The PL brand is projected to achieve 905 million in revenue for 2024, a growth of 40.72% [7] - The major product "Peptide Small Red Pen Eye Cream" has seen a significant increase in online sales, reaching 533 million, up 146% [7]